



January 25, 2021

UBC File: F20-05975

**VIA EMAIL**

Jordan Cleland  
COO  
PO Box 20002  
Towne Centre PO  
Kelowna, BC  
V1Y 9H2  
Email: [jordanc@myndsciences.com](mailto:jordanc@myndsciences.com)

Dear Mr. Cleland,

**Re: Collaborative Research Agreement between The University of British Columbia (“UBC”) and MYND Life Sciences Inc. (the “Sponsor”) effective December 21, 2020 (the “Agreement”);**

**Amendment No.1**

UBC and Sponsor have executed the Agreement and hereby agree to amend the Agreement as follows:

**Article 1.1 (b) is hereby revised to read as follows:**


“(b) **“Contract Period”** means the period commencing on the Effective Date and ending March 21, 2022.’

All other terms and conditions of the Agreement will remain in full force and effect and will continue for the duration of the Agreement. The Agreement and this Amendment No.1 will be read together and constitute one agreement.

This Amendment to the Agreement may be signed in counterparts either through original copies or by facsimile or electronically each of which will be deemed an original and all of which will constitute the same instrument.



SIGNED FOR AND ON BEHALF of  
**THE UNIVERSITY OF BRITISH COLUMBIA**  
by its duly authorized signatories:

(signed)  Mario Kasapi  
2021.01.26 14:54:13  
-08'00'

---

Name:  
Title: Associate Director, UILO  
Date:

\_\_\_\_\_  
Name:  
Title:  
Date:

(signed) Dr. J.P. Heale  
2021.01.27  
16:59:46 -08'00'

Managing Director, UILO

SIGNED FOR AND ON BEHALF of  
**MYND LIFE SCIENCES INC.**  
by its duly authorized officer:

(s) "Jordan Cleland"

---

Name: *Jordan Cleland*  
Title: *Chief Operating Officer*  
Date: *Jan 25, 2021*

Acknowledged by:

(s) "Dr. Wilfred Jefferies"

---

Dr. Wilfred A. Jefferies  
Michael Smith Laboratories  
Date: January 25, 2021